In the field of pediatric cancers, new treatments are not as frequently developed as they are for adult cancers. While there are some biological differences between childhood and adult cancers, these are not the primary reason for the lack of innovation. Instead, the way pharmaceutical companies operate financially and the existing rules governing drug development play a significant role. The development of new drugs is a costly and time-consuming process. Pharmaceutical companies often prioritize conditions that affect larger populations or have higher financial returns. Since childhood cancers are relatively rare compared to adult cancers, there is less financial incentive for companies to invest in research and development for these conditions. Regulatory requirements also influence the availability of new treatments. The approval process for new drugs is rigorous and can be lengthy, especially for rare diseases. This can deter companies from pursuing the development of new therapies for pediatric cancers, as the return on investment may not be as high or as quick as for more common conditions. Despite these challenges, some organizations and researchers are working to improve the situation. They advocate for policies that encourage drug development for children and seek alternative funding sources to support research in this area. Their goal is to ensure that children with cancer have access to the same range of effective treatments as adults.